Senti Biosciences, Inc. - Common Stock SNTI 深 沪
交易中 09-16 11:08:15 美东时间
1.3607
+0.001
+0.05%
华盛通- 最 高1.378
- 今 开1.36
- 成交量 1.95万股
- 最 低 1.34
- 昨 收 1.36
- 总市值 3559.62万
- 52周最高 16.94
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 1.26
- 委 比 -6.92%
- 总股本 2616.02万
- 历史最高 87.70
- 量 比 0.93
- 振 幅 2.79%
- 历史最低 1.26
- 每 手 1
- 风险率 1.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, announced that its Co-Founder and CEO, Dr. Timothy Lu, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8, 2025, at 2:00 PM ET. The presentation will include a live video webcast available on the company's website, with a replay archived for 90 days. Additionally, management will conduct one-on-one meetings with qua...
09-02 13:05
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Senti Bio, a clinical-stage biotech company, will present at Webull Financial's Biotech/MedTech webinar on August 19, 2025, at 2:20 PM ET. Timothy Lu, MD, PhD, CEO and Co-Founder of Senti Bio, will deliver the presentation. The event will feature insights into Senti Bio's Gene Circuit platform, which enables next-generation cell and gene therapies for incurable diseases. Registration is available at the provided link. For more details, visit Sent...
08-14 13:15
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Senti Bio, a clinical-stage biotechnology company, participated in a Virtual Investor “What This Means” segment where Kanya Rajangam, M.D., Ph.D., discussed the recommended Phase 2 dose selection for their potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, targeting relapsed/refractory hematologic malignancies, including AML. The Company leverages its synthetic biology Gene Circuit platform to engineer precise and ...
08-12 13:15
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Chardan Capital Maintains Buy on Senti Biosciences, Maintains $12 Price Target
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.
08-09 04:23
Senti Biosciences Q2 EPS $(0.56) Beats $(0.90) Estimate
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.90) by 37.78 percent. This is a 77.14 percent increase over losses of $(2.45) per share from
08-07 20:14
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Senti Bio reported Q2 2025 financial results and updates. The company advanced SENTI-202's clinical development, confirming the recommended Phase 2 dose (RP2D) for relapsed/refractory AML. It received FDA orphan drug designation for SENTI-202 and secured a $1M grant from CIRM. Leadership was bolstered with new board and advisory appointments. Senti Bio participated in investor events,raises awareness. Financials: Cash at $21.6M, R&D expenses at ...
08-07 12:05
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Senti Biosciences has confirmed the recommended Phase 2 dose (RP2D) for its SENTI-202 CAR-NK cell therapy in a Phase 1 trial for relapsed/refractory acute myeloid leukemia (AML). The RP2D is 1.5 x 10⁹ CAR+ NK cells administered on Days 0,7, and 14 of 28-day cycles following chemotherapy. The company expects to report clinical data, including efficacy and durability, from the expansion cohort before year-end. SENTI-202, a first-in-class off-the-sh...
08-05 12:30
Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Senti Biosciences, Inc. (Senti Bio), a clinical-stage biotechnology company developing next-generation cell and gene therapies, announced that its CEO, Dr. Timothy Lu, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. During the event, Dr. Lu discussed his dedication to the Company and his passion for its developing programs. The on-demand webcast is available on virtualinvestorco.com and the Investor...
07-22 12:45
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum
Senti Bio will present at the BioScience Forum in San Carlos, CA, on July 23, 2025, discussing its novel logic-gated CAR-NK cell therapy targeting leukemia while preserving healthy bone marrow. Kanya Rajangam, M.D., Ph.D., will deliver the presentation titled "Using Logic Gated CARs to Drive Cancer Treatment." Senti Bio leverages its synthetic biology Gene Circuit platform to develop precise, controllable cell and gene therapies for incurable dis...
07-21 12:55
